In The News
Judge allows ‘cutting edge’ argument in $900M class action against Colonial, CBA
Allergan hit with class action over breast implants linked to cancer
Bayer launches High Court appeal to revive Xarelto patents
ACCC accuses Webjet of misleading customers about flight prices, bookings
Real estate listings giant REA accuses rival Domain of scraping its data
Firm fees, funder’s cut slashed in $180M stolen wages class action settlement
Clayton Utz got biggest slice of government’s $600M legal spend
Lander & Rogers denies taking adverse action against wheelchair user
Keybridge shareholder can sue over $4.75M advance for Lake Como property
Real estate ‘mogul’ Sasha Hopkins slapped with $1.25M fine
Please login to bookmarkClose

Australian regenerative medicine company Mesoblast faces a shareholder class action over disclosures related to its Remestemcel-L treatment for COVID-19 complications.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au